Format

Send to

Choose Destination
Oncotarget. 2018 Feb 21;9(19):15144-15156. doi: 10.18632/oncotarget.24540. eCollection 2018 Mar 13.

Liquid biopsy provides new insights into gastric cancer.

Author information

1
Residência Multiprofissional em Oncologia, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brazil.
2
Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, Brazil.
3
Disciplina de Genética, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
4
Disciplina de Gastroenterologia Cirurgica, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
5
Laboratório de Biologia Molecular, Hospital Ophir Loyola, Belém, PA, Brazil.

Abstract

Liquid biopsies have great promise for precision medicine as they provide information about primary and metastatic tumors via a minimally invasive method. In gastric cancer patients, a large number of blood-based biomarkers have been reported for their potential role in clinical practice for screening, early diagnosis, prognostic evaluation, recurrence monitoring and therapeutic efficiency follow-up. This current review focuses on blood liquid biopsies' role and their clinical implications in gastric cancer patients, with an emphasis on circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and circulating non-coding RNAs (ncRNAs). We also provide a brief discussion of the potential and limitations of liquid biopsies use and their future use in the routine clinical care of gastric cancer.

KEYWORDS:

circulating long non-coding RNAs; circulating microRNAs; circulating tumor DNA; circulating tumor cells; precision medicine

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center